CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
InfraReDx
ClinicalTrials.gov Identifier:
NCT01268319
First received: December 28, 2010
Last updated: June 23, 2014
Last verified: June 2014
  Purpose

The CANARY (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow) Study is a pivotal trial to evaluate criteria for defining a Lipid Core Plaque (LCP) that is at high risk of rupturing during standard of care therapy and causing intra-procedural complications. If plaques that require treatment are at higher than normal risk of causing intra-procedural complications, some life threatening, the treating physician is better informed and may opt to take precautionary measures to mitigate the risk or result of a complication. The CANARY Study is also designed to evaluate the feasibility of using a distal embolization protection device (EPD) as a means to prevent heart attacks triggered by the embolization of plaque during standard care therapy. It is thought that the EPD will prevent plaque from going downstream during treatment and obstructing other heart vessels. These obstructions could cause heart attacks by preventing blood from reaching heart muscle tissue.


Condition Intervention Phase
Coronary Atherosclerosis
Myocardial Infarction
Coronary Plaque Embolization
Device: Embolic Protection Device (EPD)
Device: Intracoronary Spectroscopy and Ultrasonic Evaluation
Device: Angioplasty and Stent Implant
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Pilot Trial of the Use of a Distal Protection Device to Prevent Peri-procedural MI During Dilation of Coronary Stenoses Caused by Plaques With Large Lipid Cores

Resource links provided by NLM:


Further study details as provided by InfraReDx:

Primary Outcome Measures:
  • Evidence of Peri-procedural Myocardial Infarction as the result of standard care stenting procedure. [ Time Frame: <24 hours after percutaneous coronary intervention ] [ Designated as safety issue: No ]
    The occurrence of a peri-procedural MI in the context of the CANARY trial will be defined as an elevation of troponin I (cTnI), or troponin T (cTnT) above three times the upper limit of normal (>3xULN).


Secondary Outcome Measures:
  • Evidence of Peri-procedural Myocardial Infarction as the result of standard [ Time Frame: <24 hours after percutaneous coronary intervention ] [ Designated as safety issue: No ]
    The occurrence of a peri-procedural MI in the context of the CANARY trial will be defined as an elevation of creatine kinase myocardial band (CK-MB) biomarker above three times the upper limit of normal (>3xULN).

  • Frequency of Intraprocedural complications related to the treatment of the Target Plaque. [ Time Frame: Catheterization Start Time to Completion Time. ] [ Designated as safety issue: Yes ]
    Instances of TIMI flow degradation, Procedural Success, Dissection/Perforations, abrupt closure, thrombus generation, etc will be recorded to determine the any gross differences in event rates between the study groups.

  • Composite MACE [ Time Frame: from discharge from initial hospital stay to 30 (+/-7days) following the procedure ] [ Designated as safety issue: Yes ]
    The composite major adverse cardiac event rate (death, myocardial infarction, revascularization of the target lesion or vessel, cerebral vascualar accident will be reported for all groups at 30 days from the initial treatment (+/- 7 days).

  • Composite MACE [ Time Frame: 365 days (+/- 30days) from initial procedure ] [ Designated as safety issue: Yes ]
    The composite major adverse cardiac event rate (death, myocardial infarction, revascularization of the target lesion or vessel, cerebral vascualar accident will be reported for all groups at 365 days from the initial treatment (+/- 30 days).


Enrollment: 85
Study Start Date: March 2011
Estimated Study Completion Date: September 2014
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: (+)HR-LCP and EPD
These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation with an embolic protection device (EPD)in place prior to any angioplasty.
Device: Embolic Protection Device (EPD)
The embolic protection device consists of a protection wire, a delivery sheath, a retrieval sheath and various accessories (wire torque device, introducer, dilator tool). The wire of the EPD is used as a standard 0.014" steerable guide wire. The filter is designed for embolic debris capture while maintaining continuous blood flow. At the completion of the procedure, the filter and its contents are removed using the retrieval sheath and then removed from the patient.
Other Name: Filterwire
Device: Intracoronary Spectroscopy and Ultrasonic Evaluation
This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
Other Names:
  • LipiScan IVUS Coronary Imaging System
  • LipiScan IVUS
  • LipiScan
  • Chemogram
Device: Angioplasty and Stent Implant
The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
Placebo Comparator: (+)HR-LCP and No EPD (standard of care)
These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
Device: Intracoronary Spectroscopy and Ultrasonic Evaluation
This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
Other Names:
  • LipiScan IVUS Coronary Imaging System
  • LipiScan IVUS
  • LipiScan
  • Chemogram
Device: Angioplasty and Stent Implant
The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
Placebo Comparator: (-)HR-LCP and No EPD (standard of care)
These subjects will meet all angiographic criteria.The target plaque will NOT contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 54 Subjects who meet this criteria will be assigned (not randomized) to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
Device: Intracoronary Spectroscopy and Ultrasonic Evaluation
This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
Other Names:
  • LipiScan IVUS Coronary Imaging System
  • LipiScan IVUS
  • LipiScan
  • Chemogram
Device: Angioplasty and Stent Implant
The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Subject is at least 18 years of age
  • Subject is scheduled for an elective coronary catheterization
  • Subject is willing and able to provide informed written consent prior to the index catheterization
  • LipiScan IVUS CIS use is not contra-indicated
  • At least one submitted Chemogram is obtained entirely within a native coronary artery
  • Patient has been diagnosed with: stable angina (CCS I or CCS II);a positive functional test for ischemia (within the preceding 30 days); OR Stabilized acute coronary syndrome (unstable angina (CCS III, or CCS IV), non STEMI, or STEMI with no chest pain or other cardiac symptoms for >24 hours
  • Blood cardiac biomarker (i.e. troponin I, CK-MB) levels less than the local laboratory ULN within 12 hours of the time of PCI guidewire placement.
  • Subject is to undergo PCI of a single lesion in a single native coronary artery during the enrollment procedure.
  • There is prior intent to treat the target lesion as part of the patient's clinical care.
  • The target lesion angiographic stenosis visually estimated as >=50% and <100%
  • The target lesion reference vessel diameter must be >=2.5mm (visually estimated)
  • Total target lesion length must be ≤60 mm (visually estimated)
  • The minimum landing zone requirements for the FilterWire device can be met.
  • There must be no major side branches (>2.0 mm in diameter) within the target lesion.
  • There must be no major side branches (>2.0mm in diameter) between the target lesion and the filter nitinol loop landing zone.

Exclusion Criteria

  • Subject is currently, or within the preceding 30 days, participating in a device or pharmaceutical treatment protocol.
  • Subject life expectancy at time of enrollment is less than 2 years;
  • Subject is pregnant or suspected to be pregnant at time of enrollment
  • Prior coronary bypass graft surgery (CABG)
  • PCI performed within the 24hours prior to the start of the study procedure
  • A PCI is planned within the 30 days following the enrollment procedure.
  • Unable to take aspirin and a thienopyridine for at least 30 days
  • Patient experienced a STEMI or non STEMI within the past 24 hours
  • Documented LVEF <25%
  • the patient has multi-lesion or multi-vessel disease requiring revascularization of multiple lesions during the enrollment catheterization
  • Any angiographic evidence of thrombus in any coronary artery
  • There is evidence of dissection or procedural complication prior to randomization
  • Patient has unprotected left main (≥50% stenosis) or left main equivalent disease
  • Target Lesion is located in the distal segment of the target native coronary artery
  • Proximal bound of the target lesion is located within 3mm of the ostium of the target vessel or major side branch (>2mm diameter by visual estimate)
  • Target lesion is excessively calcified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01268319

Locations
United States, Arizona
Scottsdale Healthcare Shea
Scottsdale, Arizona, United States, 85258
United States, California
San Francisco Veterans Affairs Medical Center
San Francisco, California, United States, 94121
United States, District of Columbia
Washington Hospital Center
Washington, District of Columbia, United States, 20010
United States, Michigan
Spectrum Health System
Grand Rapids, Michigan, United States, 49503
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
United States, New York
Mount Sinai School of Medicine Hospital
New York, New York, United States, 10029
United States, Pennsylvania
Pinnacle Health Cardiovascular Insititute
Harrisburg, Pennsylvania, United States, 17101
United States, South Carolina
Medical University of South Carolina Hospital
Charleston, South Carolina, United States, 29403
United States, Texas
Veterans Affairs North Texas Health Care Systems
Dallas, Texas, United States, 75216
Sponsors and Collaborators
InfraReDx
Investigators
Principal Investigator: Gregg W. Stone, M.D. Columbia University
  More Information

No publications provided

Responsible Party: InfraReDx
ClinicalTrials.gov Identifier: NCT01268319     History of Changes
Other Study ID Numbers: 0114
Study First Received: December 28, 2010
Last Updated: June 23, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by InfraReDx:
Myocardial Infarction
percutaneous coronary intervention
embolization
necrotic core
vulnerable plaque
coronary plaque rupture

Additional relevant MeSH terms:
Atherosclerosis
Coronary Artery Disease
Myocardial Ischemia
Infarction
Myocardial Infarction
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Ischemia
Pathologic Processes
Necrosis

ClinicalTrials.gov processed this record on July 23, 2014